Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus

Circulation

Volumn 106, Issue 6, 2002, Pages 679-684

  Haffner, Steven M ^a   Greenberg, Andrew S ^a   Weston, Wayde M ^a   Chen, Hongzi ^a   Williams, Ken ^a   Freed, Martin I ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

Atherosclerosis; Cardiovascular diseases; Diabetes mellitus; Inflammation; Risk factors

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; C REACTIVE PROTEIN; GELATINASE B; INTERLEUKIN 6; PLACEBO; ROSIGLITAZONE;

ADULT; AGED; ARTICLE; ATHEROGENESIS; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DOUBLE BLIND PROCEDURE; FEMALE; HEART INFARCTION; HUMAN; INFLAMMATORY DISEASE; INSULIN RESISTANCE; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; STATISTICAL SIGNIFICANCE; UNSTABLE ANGINA PECTORIS;

BIOLOGICAL MARKERS; BODY WEIGHT; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INTERLEUKIN-6; LEUKOCYTE COUNT; MALE; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RISK FACTORS; THIAZOLES; THIAZOLIDINEDIONES; TRANSCRIPTION FACTORS;

EID: 0037031267     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000025403.20953.23     Document Type: Article

References (28)

1. Diabetes and cardiovascular disease: The Framingham study
2. Ten-year cardiovascular mortality in relation to risk factors and abnormalities in lipoprotein composition in type 2 (non-insulin-dependent) diabetic and non-diabetic subjects
3. Epidemiology of macrovascular disease in diabetes
4. Nontraditional risko factors for coronary heart disease incidence among persons with diabetes: The Atherosclerosis Risk in Communities (ARIC) Study
5. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women
6. Chronic subclinical inflammation as part of the insulin resistance syndrome: The Insulin Resistance Atherosclerosis Study (IRAS)
7. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus
8. Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: The insulin resistance atherosclerosis study
9. White blood cell count and cardiovascular disease: Insights from the Framingham Study
10. Peroxisome proliferator-activated receptor gamma activators inhibit gene expression and migration in human vascular smooth muscle cells
11. Differential effects of metformin and troglitazone on cardiovascular risk factors in patients with type 2 diabetes
12. Role of the peroxisome proliferator-activated receptors (PPAR) in atherosclerosis
13. Rosiglitazone monotherapy is effective in patients with type 2 diabetes
14. Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man
15. Effect of statin therapy on C-reactive protein levels: The pravastatin inflammation/CRP evaluation (PRINCE): A randomized trial and cohort study
16. Do interventions to reduce coronary heart disease reduce the incidence of type 2 diabetes? A possible role for inflammatory factors
17. Plasma MMP-9: A marker of carotid plaque instability
18. Circulating matrix metallo-proteinases and their inhibitors in premature coronary atherosclerosis
19. Peripheral blood levels of matrix metalloproteases-2 and -9 are elevated in patients with acute coronary syndromes
20. Evidence of increased matrix metalloproteinase-9 concentration in patients following cardiopulmonary bypass
21. Effect of hydroxymethyl glutaryl coenzyme A reductase inhibitor therapy on high sensitive C-reactive protein levels
22. Down-regulation by troglitazone of hepatic tumor necrosis factor-alpha and interleukin-6 mRNA expression in a murine model of non-insulin-dependent diabetes
23. Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance
24. In vivo myocardial protection from ischemia/reperfusion injury by the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone
25. Troglitazone treatment increases plasma vascular endothelial growth factor in diabetic patients and its mRNA in 3T3-L1 adipocytes
26. Rapid communication: Inhibitory effect of pioglitazone on carotid arterial wall thickness in type 2 diabetes
27. Pravastatin and the development of diabetes mellitus: Evidence for a protective effect in the West of Scotland Coronary Prevention Study
28. Association of serum sialic acid and MMP-9 with lipids and inflammatory markers